Why Can't We Build Better Models of Disease? Stephen H. Friend, President and Director of Sage Bionetworks, discusses this question, and provides an overview of the day's programs."
Bio
Stephen Friend
President, Co-Founder and Director of Sage Bionetworks. Dr. Friend is the President of Sage Bionetworks. He is an authority in the field of cancer biology and a leader in efforts to make large scale, data-intensive biology broadly accessible to the entire research community. Dr. Friend has been a senior advisor to the NCI, several biotech companies, a Trustee of the AACR and is a AAAS and Ashoka Fellow as well as an editorial board memeber of Open Network Biology. Dr. Friend was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center’s Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.
Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (seedialysis, prosthesis), and instruments for monitoring biological processes. Development has been particularly rapid in the area of artificial organs, which culminated in the implantation of an artificial heart into a human being in 1982. Bioengineers also develop equipment that enables humans to maintain body functions in hostile environments, such as the space suits worn by astronauts during extravehicular maneuvers.